Keros Therapeutics, Inc. - FORM S-1 - EX-23.1 - March 16, 2020

Attached files

file filename
EX-21.1 - EX-21.1 - Keros Therapeutics, Inc.d855212dex211.htm
EX-10.13 - EX-10.13 - Keros Therapeutics, Inc.d855212dex1013.htm
EX-10.12 - EX-10.12 - Keros Therapeutics, Inc.d855212dex1012.htm
EX-10.11 - EX-10.11 - Keros Therapeutics, Inc.d855212dex1011.htm
EX-10.10 - EX-10.10 - Keros Therapeutics, Inc.d855212dex1010.htm
EX-10.9 - EX-10.9 - Keros Therapeutics, Inc.d855212dex109.htm
EX-10.8 - EX-10.8 - Keros Therapeutics, Inc.d855212dex108.htm
EX-10.7 - EX-10.7 - Keros Therapeutics, Inc.d855212dex107.htm
EX-10.6 - EX-10.6 - Keros Therapeutics, Inc.d855212dex106.htm
EX-10.5 - EX-10.5 - Keros Therapeutics, Inc.d855212dex105.htm
EX-10.4 - EX-10.4 - Keros Therapeutics, Inc.d855212dex104.htm
EX-10.3 - EX-10.3 - Keros Therapeutics, Inc.d855212dex103.htm
EX-10.2 - EX-10.2 - Keros Therapeutics, Inc.d855212dex102.htm
EX-4.1 - EX-4.1 - Keros Therapeutics, Inc.d855212dex41.htm
EX-3.2 - EX-3.2 - Keros Therapeutics, Inc.d855212dex32.htm
EX-3.1 - EX-3.1 - Keros Therapeutics, Inc.d855212dex31.htm
S-1 - S-1 - Keros Therapeutics, Inc.d855212ds1.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement on Form S-1 of our report dated February 26, 2020 relating to the consolidated financial statements of Keros Therapeutics, Inc. and its subsidiary. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

March 16, 2020

Keros Therapeutics, Inc. Reports